Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Renee Clary

Allergy Bellaire, TX Physician Assistant

NPI 1841474459 CMS profile 415908

4710 Bellaire Blvd, Suite 200, Bellaire, TX 77401

Open in the dashboard

General payments

$5,190

233 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Renee Clary of Bellaire, TX is reported in the CMS Open Payments database as having received $5,190 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,840 72
2024 General $1,725 86
2023 General $368 9
2022 General $340 11
2021 General $917 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Renee Clary
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Renee Clary were reported at $1,840. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Renee Clary Allergy median Middle half National median
2019 $0 $506 $151–$1,337 $163
2020 $0 $409 $108–$1,162 $114
2021 $917 $549 $125–$1,485 $132
2022 $340 $666 $161–$1,594 $149
2023 $368 $780 $186–$1,916 $160
2024 $1,725 $1,031 $271–$2,196 $164
2025 $1,840 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $696 28 payments
  2. GlaxoSmithKline, LLC. $617 45 payments
  3. Ferring Pharmaceuticals Inc. $490 9 payments
  4. AstraZeneca Pharmaceuticals LP $483 22 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $304 13 payments
  6. CSL Behring $303 18 payments
  7. Pharming Healthcare, Inc. $274 9 payments
  8. Organon LLC $268 13 payments
  9. Genzyme Corporation $244 9 payments
  10. Octapharma USA, Inc. $202 3 payments
  11. Other $1,309 64 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,020 230 payments
  2. Education $153 2 payments
  3. Consulting Fee $18 1 payment
Products named General payments · program years 2021–2025
  1. NUCALA $531 33 payments
  2. DUPIXENT Inflammation And Immunology $370 17 payments
  3. DUPIXENT Immunology And Inflammation $326 11 payments
  4. Hizentra $303 18 payments
  5. TEZSPIRE $297 11 payments
  6. DUPIXENT Immunology $207 8 payments
  7. MENOPUR $207 7 payments
  8. CUVITRU $205 9 payments
  9. FASENRA $180 8 payments
  10. PREGNYL $177 8 payments
  11. Other $2,380 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record